No abstract available.
Asthma* ; Theophylline*

Preparation of theophylline microcapsule by the coacervation - phase seperation method. Theophylline microcapsule has been prepared by coacervation - phase seperation, using ethyl cellulose as the coating material. Ethyl cellulose sustanined significally the release of theophylline from microcapsule. Microcapsule has been used for preparation of theophylline sustained - release tablet.
Theophylline ; Capsules

The theophylline microcapsule has been prepared by spray-drying technique, using ethyl cellulose as the coating material. Ethyl cellulose sustained significally the release of theophylline from microcapsule has been used for preparation of theophylline sustained-released tablet.
Theophylline ; Capsules

No abstract available.
Asthma* ; Theophylline*

BACKGROUND: We evaluated the Vitros 950 (Johnson & Johnson Clinical Diagnostics, Inc., NY, USA) in the measurement of digoxin and theophylline levels and compared its results to those of the TDxFLx II (Abbott Laboratories, IL, USA) used for therapeutic drug monitoring (TDM) world-widely in order to assess the utility of the Vitros 950 as a TDM instrument. METHODS: From June 1997 to August 1997, 125 and 135 candidates for TDM were randomly chosen to measure digoxin and theophylline, respectively, using the Vitros 950 and TDxFLx II. The relationship between its results and those of TDxFLx II were determined. The within-run and between-run precisions of the Vitros 950 were determined using two controls (Vitros Performance Verifier I and II; J & J Clinical Diagnostics, Inc., NY, USA). The high-concentration control (Vitros Performance Verifier II) was diluted in Vitros 7% BSA to 5 dilutions. And linearity for quantitative analysis of digoxin and theophylline were determined. RESULTS: The coefficients of variation (CV) for the within-run of the Vitro 950 were 0.8% - 4.4%. And the CV for between-run precision of the Vitro 950 were 1.7% - 12.3%. The linearity of digoxin and theophylline were relatively good. The correlations (r) of digoxin and theophylline levels with those determined by the Abbott TDxFLx II were 0.95 and 0.93, respectively (P <0.001). CONCLUSIONS: The recently developed dry slide method of the Vitros 950 proves to good precision and linearity for quantitative analysis of digoxin and theophylline. Its results correlate well with those of the TDxFLx II. The Vitros 950 does not require an elaborate preparatory protocol for the sample, and is easy to use and maintain.So it is considered a highly feasible instrument for stat test.
Digoxin* ; Drug Monitoring ; Theophylline*

No abstract available.
Asthma* ; Humans ; Prednisolone* ; Theophylline*

Theophylline tablets with release action (Theo KD) was tested in dosage 100mg x 2 tablets a time each 12 hours for asthma patients, and was compared to 100mg THEOSTAT tablet with release action of Laboratoiries INAVA (France). Results: Theo KD was suitable in the treatment of 2 0r 3 degree asthma. ADRs were minor and temporary. No one stopped treatment due to ADRs
Theophylline ; Tablets ; Chemistry

No abstract available.
Ciprofloxacin* ; Enoxacin* ; Humans* ; Metabolism* ; Theophylline*

The study conducted on bronchial asthmatic patients treated at Allergic Clinic in Bach Mai Hospital. The patients treated by theophylline pill acting within 12 hours, manufactured by Hanoi College of Pharmacy combined with Central Pharmaceutical Factory No. 2, used single-blind, controlled method. The patients used 200mg dose, twice in day (8 a.m and 8 p.m), separated from each other 12 hours. Results: The change of respiratory functions are good, both groups are more than 15 percentage
Theophylline ; Clinical Chemistry Tests ; Tablets

BACKGROUND: CEDIA is a newly developed method for therapeutic drug monitoring (TDM) and has some merits such as easy application to routine chemical analyzers, rapid and precise quantitation even in low concentrations and less cross reactivity. We evaluated the CEDIA(epsilon) (Microgenics Co., CA, USA) in measurement of theophyllin, valproic acid and phenytoin levels using 502X(epsilon) (A & T, Tokyo, Japan) and compared the results to those of the TDx(epsilon) (Abbott Laboratories, IL, USA) in order to assess the utility of the CEDIA(epsilon). METHODS: We evaluated the performance of 502X(epsilon) in the aspects of the within-runs and the between-runs precision, linearity, and carry-over. We compared the results of the CEDIA(epsilon) reagent with those of TDx(epsilon). The control materials (Bio-Rad TDM control level 1 and level 3; Bio-Rad laboratories, CA, USA) and clinical specimens were used for these studies. RESULTS: The coefficients of variation (CV) for the within-run and the between-run imprecision of 502X(epsilon) were 2.0-7.6% and 4.0-6.5%, respectively. The carry-over rate for theophyllin, valproic acid and phenytoin was 1.33%, 0.45% and 0.53%, respectively. The linearity (r(2)) of theophyllin, valproic acid and phenytoin was 0.9941, 0.9983 and 0.9947, respectively. The correlation coefficients (r) of theophyllin, valproic acid and phenytoin levels of CEDIA(epsilon), with those determined by the TDx(epsilon), were 0.9730, 0.9703 and 0.9695, respectively (P<0.001). CONCLUSIONS: The recentlydeveloped CEDIA(epsilon) proved to be highly precise and linear for quantitative analysis of theophyllin, phenytoin and valproic acid. Correlations with TDx(epsilon) were significantly high. CEDIA(epsilon) was thought to be clinically useful for TDM.
Drug Monitoring ; Phenytoin* ; Theophylline* ; Valproic Acid*